KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)
Go back to KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR)| Merck & Co. (NYSE: MRK) | Delayed: 130.42 -0.5 (0.38%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $130.92 | 52 Week High | $65.46 | |||
| Open | $129.93 | 52 Week Low | $47.97 | |||
| Day High | $132.84 | P/E | 88.72 | |||
| Day Low | $129.70 | EPS | $1.47 | |||
| Volume | 6,343,840 | |||||
